Company intelligence / Profile preview

Wave Sciences

Cambridge, Massachusetts, United Stateswavesciencescorp.com ↗

Ownership: Private
Employees: ~201
Development stage: Other

Overview

Wave Life Sciences has achieved the first-ever therapeutic RNA editing in humans in its RestorAATion‑2 trial of WVE‑006 for alpha‑1 antitrypsin deficiency. The company is advancing clinical and preclinical programs targeting rare and prevalent disorders using a suite of proprietary RNA-targeting modalities. Its lead programs include candidates for alpha‑1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity

Therapeutic areas: Rare DiseasesEndocrinologyNeurology
Modalities: Antisense oligonucleotideSmall interfering RNARNA therapyRNA editing therapy (including ADAR-mediated editing)Splicing modulation (RNA splicing)
Industry: Biotech

Beyond the preview

Go deeper on Wave Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wave Sciences.

Explore the full profile